Testing effectiveness (Phase 2)Active Not RecruitingNCT05154487What this trial is testingAlpelisib and Fulvestrant to Treat Endometrial CancerWho this might be right forEndometroid Endometrial Cancer GOG Foundation 51
Testing effectiveness (Phase 2)Study completedNCT01277757What this trial is testingAkt Inhibitor MK2206 in Treating Patients With Advanced Breast CancerWho this might be right forRecurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast Cancer+1 more National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Study completedNCT02728258What this trial is testingCopanlisib in Treating Patients With Persistent or Recurrent Endometrial CancerWho this might be right forEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more NRG Oncology 11
Early research (Phase 1)Study completedNCT01226316What this trial is testingSafety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesWho this might be right forAdvanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more AstraZeneca 285
Testing effectiveness (Phase 2)Study completedNCT01704703What this trial is testingStudy of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive TechniquesWho this might be right forStage IV Colorectal Cancer Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 72
Early research (Phase 1)Looking for participantsNCT07524322What this trial is testingStudy of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsWho this might be right forBreast CancerOvarian CancerEndometrial Cancer+6 more Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Looking for participantsNCT05768139What this trial is testingFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsWho this might be right forBreast CancerSolid Tumors, Adult Eli Lilly and Company 880
Early research (Phase 1)Active Not RecruitingNCT04192981What this trial is testingGDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal MetastasesWho this might be right forBrain MetastasesLeptomeningeal Metastasis Memorial Sloan Kettering Cancer Center 21
Testing effectiveness (Phase 2)Looking for participantsNCT05455619What this trial is testingEvexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast CancerWho this might be right forHR+/HER2-negative Breast CancerMetastatic Breast Cancer SynDevRx, Inc. 52
Not applicableLooking for participantsNCT06805812What this trial is testingPredicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyWho this might be right forBreast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Early research (Phase 1)Active Not RecruitingNCT06239467What this trial is testingFirst-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerWho this might be right forAdvanced CancerBreast CancerAdvanced Solid Tumors+1 more OnKure, Inc. 200
Not applicableUnknownNCT05750693What this trial is testingPIK3CA in HER2+ BC and pCR TrialWho this might be right forHER2-positive Breast Cancer Fondazione Policlinico Universitario Agostino Gemelli IRCCS 58
Large-scale testing (Phase 3)Ended earlyNCT03439046What this trial is testingStudy of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantWho this might be right forBreast Cancer Novartis Pharmaceuticals 287
Testing effectiveness (Phase 2)Study completedNCT01625286What this trial is testingInvestigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer PatientsWho this might be right forAdvanced or Metastatic Breast CancerER+ve Advanced or Metastatic Breast Cancer AstraZeneca 148
Testing effectiveness (Phase 2)WithdrawnNCT07323576What this trial is testingEvaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal CancerWho this might be right forColorectal Cancer Hoffmann-La Roche
Not applicableEnded earlyNCT05571670What this trial is testingBile Acids in Acute Insulin ResistanceWho this might be right forPI3K Gene MutationAKT Gene MutationMTOR Gene Mutation+2 more Columbia University 3
Early research (Phase 1)Study completedNCT04344795What this trial is testingPhase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsWho this might be right forSolid TumorColorectal CancerNon Small Cell Lung Cancer+6 more Tempest Therapeutics 89
Early research (Phase 1)Study completedNCT01219699What this trial is testingBYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneWho this might be right forAdvanced Solid Tumors With an Alteration of the PIK3CA GeneEstrogen Receptor Positive Breast Cancer Novartis Pharmaceuticals 221
Testing effectiveness (Phase 2)Study completedNCT05054725What this trial is testingCombination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesWho this might be right forNon-Small Cell Lung Cancer Revolution Medicines, Inc. 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07679269What this trial is testingRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Who this might be right forPIK3CA-Related Overgrowth Spectrum (PROS)Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) Novartis Pharmaceuticals 51